Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis

Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis

Lin He,1,* Qian Wu,1,* Jing Xiong,2 Zhumin Su,3 Biyuan Zhang,4 Yuhua Song11Breast Center B Ward, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People’s Republic of China; 2Department of Geriatrics, The Affiliated Hospital of Qingdao University, Qingdao, Shandon...

Full description

Bibliographic Details
Main Authors: He L, Wu Q, Xiong J, Su Z, Zhang B, Song Y
Format: Article
Language:English
Published: Dove Medical Press 2019-08-01
Series:Cancer Management and Research
Subjects:
human epidermal growth factor receptor 2
trastuzumab
mastectomy
breast conserving therapy
breast cancer.
Online Access:https://www.dovepress.com/do-early-her2-overexpression-breast-cancer-patients-benefit-from-under-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/do-early-her2-overexpression-breast-cancer-patients-benefit-from-under-peer-reviewed-article-CMAR

Similar Items